All In Biotech

Drug Trial Radar · NCT04040192

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 3 Months and Older) With Mild-to-Moderate Atopic Dermatitis, Who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment

Last checked: Nov 20, 2026Latest source record: Mar 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

620

Actual

Start

Sep 12, 2019

Primary completion

Jan 19, 2022

Study completion Jan 19, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.

Conditions

  • Atopic Dermatitis

Interventions

  • Crisaborole 2%Drug

    Crisaborole ointment 2%

  • VehicleDrug

    Vehicle ointment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Flare-Free Maintenance Until Onset of First-Flare During the Double Blind (DB) PeriodTime frame: From randomization to first flare or last ISGA assessment (up to 52 weeks)
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Crisaborole 2% BID: From start of study intervention in OL period up to 8 weeks ; Vehicle QD and crisaborole 2% QD: From start of study intervention in DB period up to 28 days after last dose of study intervention (maximum of 56 weeks)

Locations

44 sites in 6 countries. Site status is shown where the registry gives one.

  • First OC Dermatology

    Fountain Valley, California

  • Center for Dermatology Clinical Research, Inc.

    Fremont, California

  • Asthma and Allergy Associates, PC

    Colorado Springs, Colorado

  • Colorado Springs Dermatology Clinic, PC

    Colorado Springs, Colorado

  • Skin Care Research LLC

    Boca Raton, Florida

  • Clinical Neuroscience Solutions, Inc

    Jacksonville, Florida

  • Olympian Clinical Research

    Largo, Florida

  • Baumann Cosmetic and Research Institute

    Miami, Florida

  • Clinical Neuroscience Solutions, Inc

    Orlando, Florida

  • The Indiana Clinical Trials Center, PC

    Plainfield, Indiana

  • Meridian Clinical Research, LLC

    Baton Rouge, Louisiana

  • Great Lakes Research Group, Inc.

    Bay City, Michigan

  • Skin Specialists PC

    Omaha, Nebraska

  • Ohio Pediatric Research Association, Inc.

    Dayton, Ohio

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Oklahoma State University - Center for Health Sciences

    Tulsa, Oklahoma

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee

  • Innovate Research, LLC

    Fort Worth, Texas

  • Austin Institute for Clinical Research

    Houston, Texas

  • Austin Institute for Clinical Research, Inc.

    Pflugerville, Texas

  • Center for Clinical Studies, LTD. LLP

    Webster, Texas

  • Jordan Valley Dermatology Center

    South Jordan, Utah

  • PI-Coor Clinical Research LLC

    Burke, Virginia

  • Dermatology Specialists of Spokane

    Spokane, Washington

  • Principle Research Solutions

    Spokane, Washington

  • Australian Clinical Research Network

    Maroubra, New South Wales, Australia

  • SimcoDerm Medical and Surgical Dermatology Center

    Barrie, Ontario, Canada

  • Milestone Research , Inc

    London, Ontario, Canada

  • North York Research Inc.

    North York, Ontario, Canada

  • Manna Research Toronto

    Toronto, Ontario, Canada

  • Skinsense Medical Research

    Saskatoon, Saskatchewan, Canada

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Dermatology Hospital of Jiangxi Province

    Nanchang, Jiangxi, China

  • Huashan Hospital Fudan University/Dermatology Department

    Shanghai, Shanghai Municipality, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • Hangzhou Third Hospital

    Hangzhou, Zhejiang, China

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.